Schedule of Investments | |||||||
September 30, 2023 (unaudited) | |||||||
AmericaFirst Defensive Growth Fund | |||||||
Shares or Principal | |||||||
Security Description |
|
| Amount ($) |
| Fair Value ($)(1) | ||
| |||||||
Common Stocks - 91.72% | |||||||
Aerospace & Defense - 3.99% | |||||||
Raytheon Technologies Corp. | 580 | 41,743 | |||||
Biotechnology - 14.88% | |||||||
Biogen, Inc. (2) | 630 | 47,212 | |||||
Gilead Sciences, Inc. | 185 | 47,547 | |||||
Vertex Pharmaceuticals, Inc. (2) | 174 | 60,507 | |||||
155,266 | |||||||
Consumer Staples Distribution - 2.70% | |||||||
Costco Wholesale Corp. | 50 | 28,248 | |||||
Electric Services - 9.36% | |||||||
The Southern Co. | 809 | 52,358 | |||||
Xcel Energy, Inc. | 791 | 45,261 | |||||
97,619 | |||||||
Food Products - 17.80% | |||||||
Archer-Daniels Midland Co. | 633 | 47,741 | |||||
General Mills, Inc. | 641 | 41,018 | |||||
Mondelez International, Inc. Class A | 782 | 54,271 | |||||
The Hershey Co. | 213 | 42,617 | |||||
185,647 | |||||||
Health Care Equipment and Supplies - 13.37% |
| ||||||
Abbott Laboratories | 499 | 48,328 | |||||
Medtronic Plc. Ordinary Shares | 570 | 44,665 | |||||
Stryker Corporation | 170 | 46,456 | |||||
139,449 | |||||||
Health Care Providers & Services - 6.05% | |||||||
McKesson Corp. | 145 | 63,053 | |||||
Health Care Technology - 5.91% | |||||||
Veeva Systems, Inc. Class A (2) | 303 | 61,645 | |||||
Pharmaceuticals - 13.10% | |||||||
Eli Lilly & Co. | 159 | 85,404 | |||||
Johnson & Johnson | 329 | 51,242 | |||||
136,646 | |||||||
Tobacco - 4.56% | |||||||
Philip Morris International, Inc. | 514 | 47,586 | |||||
Total Common Stock | (Cost $ 950,852) | 956,902 | |||||
Money Market Registered Investment Companies - 6.88% | |||||||
Federated Hermes Institutional Prime Obligations Fund - Institutional Class, 5.43% (4) | 71,747 | 71,747 | |||||
Total Money Market Registered Investment Companies | (Cost $ 1,022,599) | 71,747 | |||||
Total Investments - 98.64% | (Cost $ 1,022,599) | 1,028,649 | |||||
Other Assets Less Liabilities - 1.36% | 14,230 | ||||||
Total Net Assets - 100.00% | 1,042,879 | ||||||
(1) Statement on Financial Accounting Standard No. 157 "Fair Value Measurements" - Various inputs are used in determining the value of the Fund's investments. | |||||||
These inputs are summarized in the three broad levels listed below. | |||||||
• Level 1 - quoted prices in active markets for identical securities | |||||||
• Level 2 - other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.) | |||||||
• Level 3 - significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments) | |||||||
The following is a summary of the inputs used as of September 30, 2023 in valuing the Fund's assets carried at fair value: | |||||||
|
|
|
|
| Investments in |
| Other Financial |
Valuation Inputs |
|
|
| Securities |
| Instruments (3) | |
Level 1 - Quoted Prices |
|
| $ | 1,028,649 | $ | - | |
Level 2 - Other Significant Observable Inputs |
|
|
|
| - | ||
Level 3 - Significant Unobservable Inputs |
|
| - |
| - | ||
Total |
|
|
| $ | 1,028,649 | $ | 0 |
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. For example, short-term | |||||||
debt instruments and repurchase agreements with a maturity of less than 60 days are valued using amortized cost, in accordance with rules under the Investment | |||||||
Company Act of 1940. Generally, amortized cost approximates the current fair value of a security, but since the value is not obtained from a quoted price in an active | |||||||
market, such securities are reflected as Level 2. | |||||||
(2) Represents non-income producing securities. | |||||||
(4) Investment in affiliate. The yield shown represents the 7-day yield in effect at September 30, 2023. |